JBS stock price target maintained at $21 by BofA Securities

JBS reported Q4 2025 revenue of $23.06B, beating the $21.81B forecast by 5.73%, while EPS slightly missed at $0.39 vs $0.3994. BofA kept a Buy and $21.00 price target (~23% upside from $17.03) and BMO reiterated Outperform with a $20.00 target; JBS U.S. GAAP EBITDA was $1.5B (vs BMO est. $1.3B) and LTM EBITDA was $6.29B. BofA’s sensitivity shows each 100bp EBITDA margin change alters 2026 consolidated EBITDA by $285m (US beef), $185m (PPC) and $99m (Seara); a trough-margin scenario could reduce EBITDA by ~$900m, potentially moving Net Debt/EBITDA to 3.4x from 2.9x, with assumed 2026 capex of $2.4B (including $1.3B expansion).

Analysis

JBS’s current setup creates asymmetric second-order winners and losers across the protein chain: equipment and construction contractors tied to expansion capex gain optionality if projects proceed, while US-only packers and regional processors face squeezed pricing power if global export flows re-orient to lower-cost producers. Feed and freight suppliers are a hidden source of volatility — small percentage moves in corn/soy or freight rates will flow through unevenly across JBS’s geographies, amplifying consolidated margin swings even if headline volumes hold steady.

The key risk vector is liquidity sensitivity to margin compression rather than operating performance per se. A modest, sustained decline in core division margins would force either slower growth capex or incremental asset disposals, and the fastest trigger for a material repricing is a credit-rating scare from rising leverage expectations; that can play out in weeks after two consecutive weaker-than-expected quarters, and would amplify downside via tighter bank covenants and higher funding costs.

Consensus appears to underweight the working-capital and FX pass-through dynamics embedded in multinational protein businesses. Market optimism priced to operational momentum ignores the non-linear impact of capex timing and margin troughs on net leverage — meaning upside is real but conditional on a narrow execution path. Monitor upcoming quarters for signs of capex slippage or inventory digestion; both are high-information events that will re-rate risk premia quickly.

Key Decisions for Investors

• Buy JBS (JBS) equity-sized position with a protective collar (buy 9–12 month 10% OTM puts, fund by selling 30% OTM calls). Timeframe: 6–12 months. R/R: limits downside to ~10% (plus cost), targets asymmetric upside of ~25–35% if margin momentum persists while keeping financing costs contained.
• Pair trade: long JBS (JBS) / short Tyson Foods (TSN) equal-dollar exposure. Timeframe: 6–12 months. R/R: captures relative outperformance from JBS’s geographic diversification and asset optionality; stop-loss 6–8% on the pair if relative moves reverse, target 2:1 upside/downside on conviction events (EBITDA resilience or execution vs peers).
• Buy a 12-month call spread on JBS (buy 20% OTM call, sell 50% OTM call) to express a constructive but capital-efficient view. Timeframe: 12 months. R/R: limited premium outlay with high payoff if re-rating occurs, caps unlimited tail exposure from a huge rally but maximizes probability-weighted return.
• Hedge tail credit risk: purchase 1–2 year protection on JBS senior debt (or short JBS senior bonds) sized ~25% of equity exposure. Timeframe: 6–18 months. R/R: small premium to protect against event-driven downside from a rating shock or covenant strain — expensive only if fundamentals deteriorate, otherwise acts as inexpensive insurance.